+Compare
AMRX
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
1.32B

AMRX Amneal Pharmaceuticals Forecast, Technical & Fundamental Analysis

a developer of pharmaceutical products

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for AMRX with price predictions
07:00 PM EST Dec 05, 2023

AMRX in downward trend: price may drop because broke its higher Bollinger Band on November 14, 2023

AMRX broke above its upper Bollinger Band on November 14, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In of the 40 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 01, 2023. You may want to consider a long position or call options on AMRX as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AMRX just turned positive on December 04, 2023. Looking at past instances where AMRX's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

AMRX moved above its 50-day moving average on November 02, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for AMRX crossed bullishly above the 50-day moving average on November 08, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRX advanced for three days, in of 259 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 192 cases where AMRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AMRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.928) is normal, around the industry mean (47.989). P/E Ratio (70.423) is within average values for comparable stocks, (60.542). AMRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.883). AMRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.027). P/S Ratio (0.276) is also within normal values, averaging (65.502).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NASDAQ:ZTS), Teva Pharmaceutical Industries Limited (NASDAQ:TEVA), Elanco Animal Health (NASDAQ:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI), Bausch Health Companies (NASDAQ:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 2.76B. The market cap for tickers in the group ranges from 246 to 82.08B. ZTS holds the highest valuation in this group at 82.08B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 28%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was -5%. INNPF experienced the highest price growth at 6,367%, while CNTRF experienced the biggest fall at -65%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -72%. For the same stocks of the Industry, the average monthly volume growth was -49% and the average quarterly volume growth was -40%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 68
Price Growth Rating: 62
SMR Rating: 84
Profit Risk Rating: 91
Seasonality Score: 23 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

AMRX is expected to report earnings to fall 48.95% to 9 cents per share on February 29

Amneal Pharmaceuticals AMRX Stock Earnings Reports
Q4'23
Est.
$0.10
Q3'23
Beat
by $0.06
Q2'23
Beat
by $0.09
Q1'23
Beat
by $0.03
Q4'22
Beat
by $0.02
The last earnings report on November 07 showed earnings per share of 18 cents, beating the estimate of 12 cents. With 1.30M shares outstanding, the current market capitalization sits at 1.32B.
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
400 Crossing Boulevard
Phone
+1 908 947-3120
Employees
7600
Web
https://www.amneal.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TQCYX16.85N/A
N/A
Touchstone Dividend Equity Y
MELSX14.12N/A
N/A
Morgan Stanley Inst EMkts Ldrs R6
FRDTX86.70N/A
N/A
Franklin Rising Dividends C
TNSYX11.80N/A
N/A
Touchstone International Growth Y
MXERX6.28N/A
N/A
Empower S&P SmallCap 600® Index Instl

AMRX and

Correlation & Price change

A.I.dvisor tells us that AMRX and VTRS have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AMRX and VTRS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRX
1D Price
Change %
AMRX100%
-1.52%
VTRS - AMRX
33%
Poorly correlated
+0.73%
ELAN - AMRX
28%
Poorly correlated
+0.08%
EGRX - AMRX
27%
Poorly correlated
-1.00%
COLL - AMRX
27%
Poorly correlated
-0.57%
DVAX - AMRX
25%
Poorly correlated
-2.55%
More

Groups containing AMRX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRX
1D Price
Change %
AMRX100%
-1.52%
drugs
(undefined stocks)
27%
Poorly correlated
+1.31%
pharmaceuticals
(undefined stocks)
27%
Poorly correlated
+0.45%
generic drugs
(undefined stocks)
17%
Poorly correlated
-1.02%
Pharmaceuticals
(undefined stocks)
5%
Poorly correlated
-0.26%
Pharmaceuticals: Other
(undefined stocks)
5%
Poorly correlated
-0.24%